Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia
Filip Matthijssens, … , Pieter Van Vlierberghe, Ksenia Matlawska-Wasowska
Filip Matthijssens, … , Pieter Van Vlierberghe, Ksenia Matlawska-Wasowska
Published February 8, 2021
Citation Information: J Clin Invest. 2021;131(6):e141566. https://doi.org/10.1172/JCI141566.
View: Text | PDF
Research Article Oncology

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia

  • Text
  • PDF
Abstract

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with inferior outcome compared with that of B cell ALL. Here, we show that Runt-related transcription factor 2 (RUNX2) was upregulated in high-risk T-ALL with KMT2A rearrangements (KMT2A-R) or an immature immunophenotype. In KMT2A-R cells, we identified RUNX2 as a direct target of the KMT2A chimeras, where it reciprocally bound the KMT2A promoter, establishing a regulatory feed-forward mechanism. Notably, RUNX2 was required for survival of immature and KMT2A-R T-ALL cells in vitro and in vivo. We report direct transcriptional regulation of CXCR4 signaling by RUNX2, thereby promoting chemotaxis, adhesion, and homing to medullary and extramedullary sites. RUNX2 enabled these energy-demanding processes by increasing metabolic activity in T-ALL cells through positive regulation of both glycolysis and oxidative phosphorylation. Concurrently, RUNX2 upregulation increased mitochondrial dynamics and biogenesis in T-ALL cells. Finally, as a proof of concept, we demonstrate that immature and KMT2A-R T-ALL cells were vulnerable to pharmacological targeting of the interaction between RUNX2 and its cofactor CBFβ. In conclusion, we show that RUNX2 acts as a dependency factor in high-risk subtypes of human T-ALL through concomitant regulation of tumor metabolism and leukemic cell migration.

Authors

Filip Matthijssens, Nitesh D. Sharma, Monique Nysus, Christian K. Nickl, Huining Kang, Dominique R. Perez, Beatrice Lintermans, Wouter Van Loocke, Juliette Roels, Sofie Peirs, Lisa Demoen, Tim Pieters, Lindy Reunes, Tim Lammens, Barbara De Moerloose, Filip Van Nieuwerburgh, Dieter L. Deforce, Laurence C. Cheung, Rishi S. Kotecha, Martijn D.P. Risseeuw, Serge Van Calenbergh, Takeshi Takarada, Yukio Yoneda, Frederik W. van Delft, Richard B. Lock, Seth D. Merkley, Alexandre Chigaev, Larry A. Sklar, Charles G. Mullighan, Mignon L. Loh, Stuart S. Winter, Stephen P. Hunger, Steven Goossens, Eliseo F. Castillo, Wojciech Ornatowski, Pieter Van Vlierberghe, Ksenia Matlawska-Wasowska

×

Figure 4

RUNX2 genome-wide binding profiles reveal a regulatory feedback loop with KMT2A fusion proteins.

Options: View larger image (or click on image) Download as PowerPoint
RUNX2 genome-wide binding profiles reveal a regulatory feedback loop wit...
(A and B) Most highly enriched binding motifs according to HOMER upon RUNX2 ChIP-Seq in KARPAS-45 (KMT2A-R) and PER-117 (ETP). (C and D) Distribution of RUNX2 binding over different genomic regions in KARPAS-45 and PER-117. (E) MA plot showing differentially regulated genes (PAdj < 0.05) in KARPAS-45, 72 hours after shRNA-mediated RUNX2 silencing vs. control in 5 biological replicates. (F–H) Top 10 enrichments of RUNX2-binding peaks based on functional annotation provided by GREAT (3.0.0). (I) RUNX2 and H3K27ac binding profile on the KMT2A gene region in KARPAS-45. (J) ChiP-qPCR on KARPAS-45 cells and 2 KMT2A-R primary T-ALL patient samples. Enrichment of RUNX2 on KMT2A promoter (left); enrichment of N-terminus of KMT2A (KMT2AN) on RUNX2 promoter (right). (K) Luciferase reporter assay for KMT2A on HEK293 cells transduced with RUNX2 shRNA. The RUNX2 binding site is indicated as X (–359 to –368 bp upstream of KMT2A coding starting site). (L) Silencing of RUNX2 leads to decreased levels of KMT2AN in primary T-ALL samples. (M) Runx2 expression in KMT2A-MLLT1 transformed cells compared with lineage-depleted mouse progenitor cells. (N) Gradually increased expression of Runx2 measured by qRT-PCR during KMT2A-MLLT1 driven transformation over different replatings. (J) Unpaired 2-tailed t test with Holm-Šidák correction for multiple comparisons; (M) unpaired 2-tailed t test. *P < 0.05; ***P < 0.0005; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts